Other Vaccines - Gambia

Gambia

Highlights

The projected revenue for the Other Vaccines market in Gambia is expected to reach US$251.10k in 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 10.38%, leading to a market volume of US$411.50k by 2029.
In comparison to other countries worldwide, United States is expected to generate the highest revenue of US$24.73bn in 2024.
Gambia's increasing focus on expanding immunization programs highlights a growing demand for other vaccines in the country.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Gambia has been experiencing certain trends and developments that are worth exploring.

Customer preferences: Gambian customers have shown a growing awareness of the importance of vaccines in preventing diseases. This has led to an increase in demand for vaccines, including the Other Vaccines category. Customers are also becoming more price-sensitive and are looking for affordable options.

Trends in the market: The Other Vaccines market in Gambia has been growing steadily in recent years. This is due to several factors, including government initiatives to increase vaccination coverage, rising healthcare investments, and growing awareness among the population. The market has seen the entry of new players, which has led to increased competition. There has also been a shift towards combination vaccines, which offer protection against multiple diseases.

Local special circumstances: Gambia is a small country with a population of around 2 million people. The healthcare system is underdeveloped, and there are significant challenges in delivering vaccines to remote areas. The country also has a high burden of infectious diseases, such as malaria and tuberculosis, which puts additional strain on the healthcare system. These factors have contributed to the slow development of the vaccine market in Gambia.

Underlying macroeconomic factors: Gambia is one of the poorest countries in the world, with a GDP per capita of around $600. The economy is heavily reliant on agriculture, which accounts for around 30% of GDP. The country has been experiencing slow economic growth in recent years, which has limited the government's ability to invest in healthcare. However, there have been some positive developments, such as debt relief and increased donor support, which have helped to boost the healthcare sector.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.